Arvinas reports 2025 results and outlines upcoming pipeline milestones
Arvinas reported Q4 2025 revenue of $9.5 million, down from $59.2 million a year earlier. Full-year revenue was $262.6 million and operating expenses declined. The company posted a quarterly net loss per share of $1.10. Multiple clinical milestones are expected in 2026, including ARV-102 updates in Parkinson's disease, oncology readouts for ARV-806 and ARV-393, a Phase 1 start for ARV-027, and a planned Phase 1 for HPK1 degrader ARV-6723.
Why it matters2026 readouts for ARV-102 (Parkinson's) and ARV-806/393 could shift partnership and investment timelines.
Entities Mentioned
Arvinas